Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease.

about

Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease.

Item

http://www.wikidata.org/entity/Q54117927

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Dual mTOR/PI3K inhibition limi ...... ant polycystic kidney disease.

@en

Dual mTOR/PI3K inhibition limi ...... ant polycystic kidney disease.

@nl

type

Item

label

Dual mTOR/PI3K inhibition limi ...... ant polycystic kidney disease.

@en

Dual mTOR/PI3K inhibition limi ...... ant polycystic kidney disease.

@nl

prefLabel

Dual mTOR/PI3K inhibition limi ...... ant polycystic kidney disease.

@en

Dual mTOR/PI3K inhibition limi ...... ant polycystic kidney disease.

@nl

P1476

Dual mTOR/PI3K inhibition limi ...... ant polycystic kidney disease.

@en

P2093

Alexandre Arcaro

http://www.w3.org/2001/XMLSchema#string

Andreas L Serra

http://www.w3.org/2001/XMLSchema#string

Deborah Castelletti

http://www.w3.org/2001/XMLSchema#string

Harald Mischak

http://www.w3.org/2001/XMLSchema#string

Martin Pejchinovski

http://www.w3.org/2001/XMLSchema#string

Terry J Watnick

http://www.w3.org/2001/XMLSchema#string

William Mullen

http://www.w3.org/2001/XMLSchema#string

Xuebin Fu

http://www.w3.org/2001/XMLSchema#string

Xueqi Wang

http://www.w3.org/2001/XMLSchema#string

Yang Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Activation of the PI3K/mTOR pathway is involved in cystic proliferation of cholangiocytes of the PCK rat

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

Cellular mechanisms of tissue fibrosis. 6. Purinergic signaling and response in fibroblasts and tissue fibrosis

Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.

Polycystic kidney disease.

FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway

P2888

s41598-018-22938-x

P304

5584

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-018-22938-X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Justyna Siwy

P577

2018-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1101852971

http://www.w3.org/2001/XMLSchema#string

P698

29615724

http://www.w3.org/2001/XMLSchema#string

P921

autosomal dominant polycystic kidney disease

P932

5882886

http://www.w3.org/2001/XMLSchema#string